Skip to content
Catalyst

methylphenidateWhat was measured

Measured, with no finding

626 endpoints

Show what was measuredHide what was measured
  • decreased appetite, number needed to treat

    increases

    For example, clinicians only need to treat 4 children to identify an episode of decreased appetite

    PMID 11762571 · one of two readings recorded this

  • hyperactivity index, parent reported

    decreases

    Each primary outcome (hyperactivity index) demonstrated a significant effect of methylphenidate (effect size reported by teacher 0.78, 95% confidence interval [CI] 0.64-0.91; effect size reported by parent 0.54, 95% CI 0.40-0.67)

    PMID 11762571 · one of two readings recorded this

  • hyperactivity index reported by teacher and by parent, pooled effect size; decreased appetite as an adverse event

    effect size reported by teacher 0.78, 95% CI 0.64-0.91; reported by parent 0.54, 95% CI 0.40-0.67

    Not recorded as a finding: this platform holds no node for the endpoint

    Each primary outcome (hyperactivity index) demonstrated a significant effect of methylphenidate (effect size reported by teacher 0.78, 95% confidence interval [CI] 0.64-0.91; effect size reported by parent 0.54, 95% CI 0.40-0.67).

    PMID 11762571 · one of two readings recorded this

  • hyperactivity index, teacher reported

    decreases

    Each primary outcome (hyperactivity index) demonstrated a significant effect of methylphenidate (effect size reported by teacher 0.78, 95% confidence interval [CI] 0.64-0.91; effect size reported by parent 0.54, 95% CI 0.40-0.67)

    PMID 11762571 · one of two readings recorded this

  • ADHD symptom severity on the ADHDRS-IV Parent:Inv, standardised mean difference of methylphenidate versus atomoxetine; response rate; all-cause discontinuation

    no effect, SMD 0.09 (95% CI -0.08-0.26), p = 0.29

    Not recorded as a finding: the comparison was against another active treatment

    Meta-analysis did not find a significant difference in efficacy between methylphenidate and atomoxetine when standardized mean difference (SMD) was used as a measure of effect size 0.09 (95% CI -0.08-0.26) (Z = 1.06, p = 0.29).

    PMID 22074258 · one of two readings recorded this

  • ADHDRS-IV Parent:Inv efficacy, pooled SMD

    no effect, p = 0.29, n = 2762

    Meta-analysis did not find a significant difference in efficacy between methylphenidate and atomoxetine when standardized mean difference (SMD) was used as a measure of effect size 0.09 (95% CI -0.08-0.26) (Z = 1.06, p = 0.29)

    PMID 22074258 · one of two readings recorded this

  • ADHDRS-IV Parent:Inv efficacy, pooled SMD

    no effect, p = 0.64

    Immediate release methylphenidate was not superior to atomoxetine SMD -0.04 (95% CI -0.19-0.12) (Z = 0.46, p = 0.64)

    PMID 22074258 · one of two readings recorded this

  • ADHDRS-IV Parent:Inv efficacy, pooled SMD

    no effect, p = 0.22

    Excluding the cross over trial too did not change the results significantly 0.11 (95% CI -0.07-0.29) (Z = 1.23 p = 0.22)

    PMID 22074258 · one of two readings recorded this

  • ADHDRS-IV Parent:Inv efficacy, pooled SMD

    no effect, p = 0.2

    Excluding open label trials did not significantly alter the pooled standardized mean difference 0.08 (95% CI -0.04-0.21) (Z = 1.27, p = 0.20)

    PMID 22074258 · one of two readings recorded this

  • ADHDRS-IV Parent:Inv efficacy, pooled SMD

    increases, p = 0.002

    Sub group analysis showed a significant standardized mean difference favouring OROS methylphenidate 0.32 (95% CI 0.12-0.53 (Z = 3.05, p < 0.002)

    PMID 22074258 · one of two readings recorded this

  • all-cause discontinuation

    no effect, p = 0.25

    There was no significant difference in all cause discontinuation between atomoxetine and methylphenidate (RR 1.22, 95% CI 0.87-1.71, p = 0.25)

    PMID 22074258 · one of two readings recorded this

  • between-study heterogeneity of SMD

    unclear, p = 0.002

    There was significant heterogeneity among the studies (p = 0.002, I2 = 67%)

    PMID 22074258 · one of two readings recorded this

  • between-study heterogeneity of SMD

    no effect, p = 0.48

    There was no significant heterogeneity among double blind trials (p = 0.48 I2 = 0%)

    PMID 22074258 · one of two readings recorded this

  • between-study heterogeneity of SMD

    unclear, p = 0.001

    Subgroup analysis found that the heterogeneity was due to the open label trials (p = 0.001, I2 = 81%)

    PMID 22074258 · one of two readings recorded this

  • response rate

    no effect, p = 0.49

    There was no significant difference in response rates between the two medications (RR = 0.93 95% CI 0.76-1.14, p = 0.49)

    PMID 22074258 · one of two readings recorded this

  • adverse effect anorexia

    increases, p = 0.02

    Anorexia | 2 | 121/123 | 2.18 [1.15, 4.14] | 0.02 | 0

    PMID 24416225 · one of two readings recorded this

  • adverse effect anxiety

    increases, p = 0.005

    Anxiety | 2 | 145/148 | 2.50 [1.32, 4.73] | 0.005 | 0

    PMID 24416225 · one of two readings recorded this

  • adverse effect insomnia

    no effect, p = 0.23

    Insomnia | 2 | 128/131 | 1.46 [0.78, 2.74] | 0.23 | 0

    PMID 24416225 · one of two readings recorded this

  • adverse effect nausea

    increases, p = 0.001

    Nausea | 2 | 110/112 | 4.65 [1.84, 11.77] | 0.001 | 0

    PMID 24416225 · one of two readings recorded this

  • adverse effect tachycardia

    no effect, p = 0.47

    Tachycardia | 3 | 96/100 | 0.66 [0.21, 2.06] | 0.47 | 40

    PMID 24416225 · one of two readings recorded this

  • adverse effect vertigo

    increases, p = 0.004

    Vertigo | 2 | 128/131 | 3.74 [1.52, 9.16] | 0.004 | 0

    PMID 24416225 · one of two readings recorded this

  • baseline BFI, Moraska 2010

    Moraska et al, 2010 | 62 | 63 | 40% | 60 | 4 | 54 | Mixed tumor | Fatigue | BFI: 3.36±1.54/3.4±1.72 | USA | parallel | 5

    PMID 24416225 · one of two readings recorded this

  • baseline BFI, Roth 2010

    Roth et al, 2010 | 10 | 13 | 100% | 70 | 6 | 30 | Prostate cancer | Fatigue | BFI: 5.13±2.25/4.01±2. 00 | USA | parallel | 3

    PMID 24416225 · one of two readings recorded this

  • baseline FACT-F, Bruera 2006

    Bruera et al, 2006 | 52 | 53 | 37% | 57 | 1 | 20 | Mixed tumor | Fatigue | FACT-F: 16.87±7.96/17.04±7.98 | USA | parallel | 5

    PMID 24416225 · one of two readings recorded this

  • baseline FACT-F, Butler 2007

    Butler et al, 2007 | 20 | 21 | 54% | 56 | 4 | 30 | Primary brain tumor | Fatigue | FACT-F: 34.7±8.04/33.3±12.92 | USA | parallel | 4

    PMID 24416225 · one of two readings recorded this

  • baseline FACT-F, Lower 2009

    Lower et al, 2009 | 54 | 69 | 10% | 53 | 8 | 28 | Mixed tumor | Fatigue | FACT-F: 30.9±10.2/30.0±10.1 | USA | parallel | 5

    PMID 24416225 · one of two readings recorded this

  • BFI severity scores decrease

    decreases, p = 0.03

    greater decrease on BFI severity scores (p = 0.03)

    PMID 24416225 · one of two readings recorded this

  • BFI total scores decrease

    decreases, p = 0.03

    a trend toward greater decrease on BFI total scores (p = 0.03)

    PMID 24416225 · one of two readings recorded this

  • cancer-related fatigue, BFI

    no effect, p = 0.23

    The Other two studies used the BFI, with an overall mean difference of −0.69 (95% [CI] −1.81–0.43), suggesting no significant effect of methylphenidate on CRF (p = 0.23)

    PMID 24416225 · one of two readings recorded this

  • cancer-related fatigue, FACT-F

    decreases, p = 0.01

    The overall mean difference was −3.13 (95% confidence interval [CI] −5.55– −0.71), suggesting significant effect of methylphenidate on CRF (p = 0.01)

    PMID 24416225 · one of two readings recorded this

  • cancer-related fatigue, long-time treatment group

    decreases, p = 0.03

    Long-time group's overall mean difference was −3.70 (95% [CI] −7.03–−0.37; P = 0.03)

    PMID 24416225 · one of two readings recorded this

  • cancer-related fatigue on FACT-F, pooled mean difference

    MD -3.13, 95% CI -5.55 to -0.71, p = 0.01

    Not recorded as a finding: direction carried only by a signed estimate; the sentence says 'significant effect' without a direction word

    The overall mean difference was −3.13 (95% confidence interval [CI] −5.55– −0.71), suggesting significant effect of methylphenidate on CRF (p = 0.01).

    PMID 24416225 · one of two readings recorded this

  • cancer-related fatigue, short-time treatment group

    no effect, p = 0.17

    short-time group's overall mean difference was −2.49 (95% [CI] −6.01–1.03; P = 0.17)

    PMID 24416225 · one of two readings recorded this

  • cognition associated with cancer-related fatigue, pooled SMD across MMSE and HSCS

    no effect, SMD -0.35, 95% CI -3.72 to 3.02, p = 0.84

    Not recorded as a finding: no node for cognition pooled across MMSE and High Sensitivity Cognitive Screen

    The pooled standardized mean difference demonstrated no impact of methylphenidate on cognition associated with CRF (−0.35, 95%CI −3.72–3.02, p = 0.84, I2 = 0%).

    PMID 24416225 · one of two readings recorded this

  • cognition associated with CRF

    no effect, p = 0.84

    The pooled standardized mean difference demonstrated no impact of methylphenidate on cognition associated with CRF (−0.35, 95%CI −3.72–3.02, p = 0.84, I2 = 0%)

    PMID 24416225 · one of two readings recorded this

  • depression associated with cancer-related fatigue, pooled SMD across ESAS-D and CES-D

    no effect, SMD -0.09, 95% CI -1.13 to 0.95, p = 0.86

    Not recorded as a finding: no node for depression symptom severity pooled across two named scales

    The pooled standardized mean difference demonstrated no impact of methylphenidate on depression associated with CRF (−0.09, 95%CI −1.13–0.95, p = 0.86, I2 = 0%).

    PMID 24416225 · one of two readings recorded this

  • depression associated with CRF

    no effect, p = 0.86

    The pooled standardized mean difference demonstrated no impact of methylphenidate on depression associated with CRF (−0.09, 95%CI −1.13–0.95, p = 0.86, I2 = 0%)

    PMID 24416225 · one of two readings recorded this

  • FACT-F fatigue, methylphenidate versus placebo at day 8

    no effect

    no statistically significant difference was found between methylphenidate and placebo group on day 8

    PMID 24416225 · one of two readings recorded this

  • study discontinuation due to side effects

    no effect, p = 0.17

    The overall risk ratio for study discontinuation due to side effects didn't suggest statistical significance between patients treated with methylphenidate and patients with placebo (RR 2.38, 95% CI 0.69–8.29, p = 0.17, I2 = 8%)

    PMID 24416225 · one of two readings recorded this

  • decreased appetite and sleep problems as adverse events, risk ratio

    increases, decreased appetite RR 3.66, 95% CI 2.56 to 5.23; 16 trials, 2962 participants

    Not recorded as a finding: no node for specific non-serious adverse events; supplement-adverse-event-incidence is bound to oral or enteral supplements and any adverse event

    Children in the methylphenidate group were at 60% greater risk for trouble sleeping/sleep problems (RR 1.60, 95% CI 1.15 to 2.23; 13 trials, 2416 participants), and 266% greater risk for decreased appetite (RR 3.66, 95% CI 2.56 to 5.23; 16 trials, 2962 participants) than children in the control group.

    PMID 26599576 · one of two readings recorded this

  • decreased appetite

    increases, n = 2962

    266% greater risk for decreased appetite (RR 3.66, 95% CI 2.56 to 5.23; 16 trials, 2962 participants)

    PMID 26599576 · one of two readings recorded this

  • non-serious adverse events, any, Trial Sequential Analysis adjusted

    increases

    The Trial Sequential Analysis-adjusted intervention effect was RR 1.29 (CI 1.06 to 1.56)

    PMID 26599576 · one of two readings recorded this

  • non-serious adverse events, any

    increases, n = 3132

    This equates to a 29% increase in the overall risk of any non-serious adverse events (RR 1.29, 95% CI 1.10 to 1.51; 21 trials, 3132 participants; very low-quality evidence)

    PMID 26599576 · one of two readings recorded this

  • parent-reported quality of life on CHQ

    increases

    The change reported in a meta-analysis of three trials corresponds to a MD of 8.0 points (95% CI 5.49 to 10.46) on the CHQ

    PMID 26599576 · one of two readings recorded this

  • parent-reported quality of life

    increases, n = 514

    methylphenidate may improve parent-reported quality of life (SMD 0.61, 95% CI 0.42 to 0.80; 3 trials, 514 participants; very low-quality evidence)

    PMID 26599576 · one of two readings recorded this

  • serious adverse events, pooled risk ratio

    RR 0.98, 95% CI 0.44 to 2.22; 9 trials, 1532 participants

    Not recorded as a finding: node serious-adverse-event-incidence exists but the only sentence is a one-sided negation ('no evidence ... increase'), which does not establish no_effect

    There was no evidence that methylphenidate was associated with an increase in serious (e.g. life threatening) adverse events (risk ratio (RR) 0.98, 95% CI 0.44 to 2.22; 9 trials, 1532 participants; very low-quality evidence).

    PMID 26599576 · one of two readings recorded this

  • serious adverse events, Trial Sequential Analysis adjusted

    no effect

    The Trial Sequential Analysis-adjusted intervention effect was RR 0.91 (CI 0.02 to 33.2)

    PMID 26599576 · one of two readings recorded this

  • serious adverse events

    no effect, n = 1532

    There was no evidence that methylphenidate was associated with an increase in serious (e.g. life threatening) adverse events (risk ratio (RR) 0.98, 95% CI 0.44 to 2.22; 9 trials, 1532 participants; very low-quality evidence)

    PMID 26599576 · one of two readings recorded this

  • sleep problems

    increases, n = 2416

    Children in the methylphenidate group were at 60% greater risk for trouble sleeping/sleep problems (RR 1.60, 95% CI 1.15 to 2.23; 13 trials, 2416 participants)

    PMID 26599576 · one of two readings recorded this

  • teacher-rated ADHD symptoms, ADHD Rating Scale

    decreases, SMD -0.77, 95% CI -0.90 to -0.64; 19 trials, 1698 participants

    Not recorded as a finding: no node for ADHD symptom severity on the ADHD-RS or pooled across teacher scales

    Methylphenidate may improve teacher-rated ADHD symptoms (standardised mean difference (SMD) -0.77, 95% confidence interval (CI) -0.90 to -0.64; 19 trials, 1698 participants; very low-quality evidence).

    PMID 26599576 · both readings recorded this

  • teacher-rated ADHD symptoms on ADHD-RS

    decreases

    This corresponds to a mean difference (MD) of -9.6 points (95% CI -13.75 to -6.38) on the ADHD Rating Scale (ADHD-RS; range 0 to 72 points; DuPaul 1991a)

    PMID 26599576 · one of two readings recorded this

  • teacher-rated ADHD symptoms

    decreases, n = 1698

    Methylphenidate may improve teacher-rated ADHD symptoms (standardised mean difference (SMD) -0.77, 95% confidence interval (CI) -0.90 to -0.64; 19 trials, 1698 participants; very low-quality evidence)

    PMID 26599576 · one of two readings recorded this

  • teacher-rated general behaviour

    decreases, n = 668

    Teacher-rated general behaviour seemed to improve with methylphenidate (SMD -0.87, 95% CI -1.04 to -0.71; 5 trials, 668 participants; very low-quality evidence)

    PMID 26599576 · one of two readings recorded this

  • ADHD symptoms by rater

    decreases, n = 1826

    observer rated (−0.61, −0.87 to −0.35, nine trials, 1826 participants)

    PMID 26608309 · one of two readings recorded this

  • ADHD symptoms by rater

    decreases, p = 0.37, n = 2179

    parent rated (−0.65, −0.81 to −0.50, 21 trials, 2179 participants), test for subgroup difference, P=0.37

    PMID 26608309 · one of two readings recorded this

  • ADHD symptoms by rater

    decreases, n = 1689

    teacher rated (−0.78, −0.93 to −0.63, 19 trials, 1689 participants)

    PMID 26608309 · one of two readings recorded this

  • ADHD symptoms in crossover trials, carry-over analysis

    decreases, n = 372

    First period (−0.64, −0.85 to −0.44, four trials, 372 participants)

    PMID 26608309 · one of two readings recorded this

  • ADHD symptoms in crossover trials, carry-over analysis

    decreases, p = 0.1, n = 372

    second period (−0.91, −1.18 to −0.65, four trials, 372 participants; test for subgroup difference, P=0.1)

    PMID 26608309 · one of two readings recorded this

  • ADHD symptoms (parallel and first period crossover trials)

    unclear, p = 0.05, n = 559

    compared to the combined type (0.65, −1.30 to 2.60, two trials, 559 participants; test for subgroup difference, P=0.05)

    PMID 26608309 · one of two readings recorded this

  • ADHD symptoms (parallel and first period crossover trials)

    decreases, n = 204

    a higher intervention effect for the inattentive subtype (standardised mean difference −1.31, 95% confidence interval −1.61 to −1.01, one trial, 204 participants)

    PMID 26608309 · one of two readings recorded this

  • Decreased appetite (crossover trials)

    increases, n = 3862

    decreased appetite (3.04, 2.35 to 3.94, 35 trials, 3862 participants, I2=40%)

    PMID 26608309 · one of two readings recorded this

  • Decreased appetite (parallel group trials)

    increases, n = 2962

    The most common non-serious adverse events were decreased appetite (risk ratio 3.66, 95% confidence interval 2.56 to 5.23, 16 trials, 2962 participants; I2=18%)

    PMID 26608309 · one of two readings recorded this

  • General behaviour (crossover trials)

    decreases, n = 2014

    The crossover trial analysis also showed a beneficial treatment effect (standardised mean difference −0.69, 95% confidence interval −0.78 to −0.60, 16 trials, 2014 participants)

    PMID 26608309 · one of two readings recorded this

  • Non-serious adverse events (crossover trials, end of second period)

    increases, n = 2072

    For these trials methylphenidate was associated with an overall increase in total number of non-serious adverse events (risk ratio 1.33, 95% confidence interval 1.11 to 1.58, 21 trials, 2072 participants)

    PMID 26608309 · one of two readings recorded this

  • Non-serious adverse events (parallel group trials)

    increases, n = 3132

    Methylphenidate was associated with an overall risk of total number of non-serious adverse events by 29% (risk ratio 1.29, 95% confidence interval 1.10 to 1.51, 21 trials, 3132 participants, fig 5)

    PMID 26608309 · one of two readings recorded this

  • Non-serious adverse events (parallel group trials)

    no effect, p = 0.57

    which did not seem to be related to dose (test for subgroup difference between low dose and high dose methylphenidate, P=0.57)

    PMID 26608309 · one of two readings recorded this

  • Non-serious adverse events, trial sequential analysis adjusted

    increases

    The trial sequential analysis adjusted risk ratio was 1.29 (95% confidence interval 1.06 to 1.56)

    PMID 26608309 · one of two readings recorded this

  • Publication bias, teacher-rated ADHD symptoms (Egger's test)

    no effect, p = 0.81

    No publication bias was detected (Egger’s test P=0.81)

    PMID 26608309 · one of two readings recorded this

  • Quality of life, child health questionnaire mean difference

    increases

    which corresponds on the child health questionnaire scale to a mean difference of 8.0 points (95% confidence interval 5.49 to 10.46)

    PMID 26608309 · one of two readings recorded this

  • quality of life on the child health questionnaire (parent-rated, three parallel-group trials), methylphenidate versus placebo or no intervention

    increases, SMD 0.61, 95% CI 0.42 to 0.80, three trials, 514 participants, n = 514

    Not recorded as a finding: the supporting sentence never names the compound

    There was a small beneficial effect on quality of life (standardised mean difference 0.61, 95% confidence interval 0.42 to 0.80, three trials, 514 participants, fig 8), which corresponds on the child health questionnaire scale to a mean difference of 8.0 points (95% confidence interval 5.49 to 10.46), which is larger than the minimal clinical relevant difference of 7.0.

    PMID 26608309 · one of two readings recorded this

  • Quality of life (parallel group trials)

    increases, n = 514

    There was a small beneficial effect on quality of life (standardised mean difference 0.61, 95% confidence interval 0.42 to 0.80, three trials, 514 participants, fig 8)

    PMID 26608309 · one of two readings recorded this

  • Serious adverse events (crossover trials, end of last period)

    no effect, n = 1721

    These trials did not seem to differ between intervention groups (risk ratio 1.62, 95% confidence interval 0.34 to 7.71, 1721 participants; I2=0%, P=0.65)

    PMID 26608309 · one of two readings recorded this

  • Serious adverse events (parallel group trials)

    no effect, n = 1532

    For these trials methylphenidate was not associated with an overall increase in total number of serious adverse events (risk ratio 0.98, 95% confidence interval 0.44 to 2.22, 1532 participants, fig 3)

    PMID 26608309 · one of two readings recorded this

  • Serious adverse events, trial sequential analysis adjusted

    no effect

    The trial sequential analysis adjusted intervention effect is risk ratio 0.91% (95% confidence interval 0.02 to 33.2)

    PMID 26608309 · one of two readings recorded this

  • Sleep problems (crossover trials)

    increases, n = 3270

    sleep problems (1.57, 1.20 to 2.06, 31 trials, 3270 participants, I2=47%)

    PMID 26608309 · one of two readings recorded this

  • Sleep problems (parallel group trials)

    increases, n = 2416

    sleep problems (1.60, 1.15 to 2.23, 13 trials, 2416 participants; I2=0%)

    PMID 26608309 · one of two readings recorded this

  • Teacher-rated ADHD symptoms, ADHD rating scale mean difference

    decreases

    This corresponds to a mean difference of −9.6 points (95% confidence interval −13.75 to −6.38) on the ADHD rating scale

    PMID 26608309 · one of two readings recorded this

  • Teacher-rated ADHD symptoms by scale type

    unclear, p = 0.006

    The intervention effect was significantly influenced by choice of scale (test for subgroup differences, P=0.006)

    PMID 26608309 · one of two readings recorded this

  • Teacher-rated ADHD symptoms (end of last period crossover trials)

    decreases, n = 5145

    The end of last period crossover trials also showed a significant treatment effect, with a standardised mean difference of −0.93 (95% confidence interval −1.06 to −0.80, 59 trials, 5145 participants)

    PMID 26608309 · one of two readings recorded this

  • Teacher-rated ADHD symptoms (end of last period crossover trials)

    decreases, n = 3413

    The benefit, however, was significantly greater with higher doses of methylphenidate (−0.98, −1.13 to −0.84, 36 trials, 3413 participants)

    PMID 26608309 · one of two readings recorded this

  • Teacher-rated ADHD symptoms (end of last period crossover trials)

    decreases, p = 0.02, n = 3408

    compared to low doses (−0.73, −0.89 to −0.57, 42 trials, 3408 participants; test for subgroup difference, P=0.02)

    PMID 26608309 · one of two readings recorded this

  • Teacher-rated ADHD symptoms (end of last period crossover trials)

    no effect, p = 0.09

    that was not significantly influenced by risk of bias (test for subgroup difference, P=0.09)

    PMID 26608309 · one of two readings recorded this

  • Teacher-rated ADHD symptoms (parallel group trials)

    decreases, n = 1698

    The results showed an effect of methylphenidate on teacher rated symptoms in the parallel group trials (standardised mean difference −0.77, 95% confidence interval −0.90 to −0.64, 19 trials, 1698 participants, fig 2)

    PMID 26608309 · one of two readings recorded this

  • Teacher-rated ADHD symptoms (parallel group trials)

    decreases, n = 253

    Long term trials had a smaller effect (standardised mean difference −0.47, 95% confidence interval −0.72 to −0.22, one trial, 253 participants)

    PMID 26608309 · one of two readings recorded this

  • Teacher-rated ADHD symptoms (parallel group trials)

    decreases, p = 0.04, n = 431

    compared to trials including participants naive to the drugs (−0.63, −0.94 to −0.31, four trials, 431 participants; test for subgroup difference, P=0.04)

    PMID 26608309 · one of two readings recorded this

  • Teacher-rated ADHD symptoms (parallel group trials)

    decreases, n = 286

    Trials including participants with previous use of drugs before randomisation resulted in a larger effect (−1.06, −1.33 to −0.79, two trials, 286 participants)

    PMID 26608309 · one of two readings recorded this

  • Teacher-rated ADHD symptoms (parallel group trials)

    decreases, p = 0.02, n = 1445

    short term trials (−0.81, −0.94 to −0.68, 18 trials, 1445 participants; test for subgroup difference, P=0.02)

    PMID 26608309 · one of two readings recorded this

  • teacher-rated ADHD symptoms, SMD pooled across scales (ADHD rating scale equivalent)

    SMD -0.77, 95% CI -0.90 to -0.64; 19 trials, 1698 participants, n = 1698

    Not recorded as a finding: no node for ADHD symptom severity pooled across teacher-rated scales

    The results showed an effect of methylphenidate on teacher rated symptoms in the parallel group trials (standardised mean difference −0.77, 95% confidence interval −0.90 to −0.64, 19 trials, 1698 participants, fig 2).

    PMID 26608309 · one of two readings recorded this

  • Teacher-rated general behaviour (parallel group trials)

    decreases, n = 668

    The standardised mean difference of teacher rated general behaviour in parallel group trials was −0.87 (95% confidence interval −1.04 to −0.71, five trials, 668 participants, fig 7)

    PMID 26608309 · one of two readings recorded this

  • teacher-rated general behaviour, SMD pooled across psychometric instruments

    SMD -0.87, 95% CI -1.04 to -0.71; five trials, 668 participants, n = 668

    Not recorded as a finding: no node for general behaviour at school and home

    The standardised mean difference of teacher rated general behaviour in parallel group trials was −0.87 (95% confidence interval −1.04 to −0.71, five trials, 668 participants, fig 7).

    PMID 26608309 · one of two readings recorded this

  • total non-serious adverse events, pooled risk ratio, parallel group trials

    increases, RR 1.29, 95% CI 1.10 to 1.51; 21 trials, 3132 participants, n = 3132

    Not recorded as a finding: near miss: supplement-adverse-event-incidence is bound to oral or enteral supplements and adverse-reaction-incidence-ungraded to reactions attributed to the product; this is all non-serious events of any kind

    Methylphenidate was associated with an overall risk of total number of non-serious adverse events by 29% (risk ratio 1.29, 95% confidence interval 1.10 to 1.51, 21 trials, 3132 participants, fig 5).

    PMID 26608309 · one of two readings recorded this

  • total serious adverse events, pooled risk ratio, parallel group trials

    RR 0.98, 95% CI 0.44 to 2.22; 1532 participants, n = 1532

    Not recorded as a finding: node serious-adverse-event-incidence exists but the sentence is a one-sided negation ('not associated with an overall increase'), which does not establish no_effect

    For these trials methylphenidate was not associated with an overall increase in total number of serious adverse events (risk ratio 0.98, 95% confidence interval 0.44 to 2.22, 1532 participants, fig 3).

    PMID 26608309 · one of two readings recorded this

  • diastolic blood pressure change at 12 months

    no effect

    Arcieri et al. reported no statistically significant effects on DBP (+0.13 mmHg) and SBP (+0.36 mmHg) at 12 months in comparison with baseline

    PMID 28236285 · one of two readings recorded this

  • diastolic blood pressure change at 12 months

    increases

    and at 12 months (DBP +1.6 mmHg; SBP +1.6 mmHg; HR +5.6 bpm) compared with baseline

    PMID 28236285 · one of two readings recorded this

  • diastolic blood pressure change at 24 months

    no effect

    There were no statistically significant effects at 24 months in comparison with the baseline (DBP +1.11 mmHg; SBP +2.13 mmHg; HR +0.21 bpm)

    PMID 28236285 · one of two readings recorded this

  • diastolic blood pressure change at 6 months

    increases

    Fuentes et al. observed small changes at 6 months for all cardiovascular parameters (DBP +1.3 mmHg; SBP +0.8 mmHg; HR +7.9 bpm)

    PMID 28236285 · one of two readings recorded this

  • diastolic blood pressure change at first measurement

    increases

    (average 6 weeks; mean changes: DBP +1 mmHg; SBP +0.75 mmHg; HR +3.35 bpm)

    PMID 28236285 · one of two readings recorded this

  • diastolic blood pressure change at first measurement

    increases

    A peak in DBP (mean +1.7 mmHg) and HR (mean +3.7 bpm) was reported at the first measurement (average 3.2 months after baseline)

    PMID 28236285 · one of two readings recorded this

  • diastolic blood pressure pre-post, effect of study duration

    increases

    Studies <18 weeks reported higher ESs (SMD 0.28) compared with longer duration studies (SMD 0.05)

    PMID 28236285 · one of two readings recorded this

  • diastolic blood pressure pre-post, effect of study duration

    increases

    Studies <18 weeks reported higher ESs (SMD 0.28) compared with longer duration studies (SMD 0.05)

    PMID 28236285 · one of two readings recorded this

  • diastolic blood pressure pre-post, moderator test of study duration

    modulates, p = 0.05

    Sensitivity analyses revealed a significant effect of study duration on DBP following AMP treatment (F(1) = 19.55, p = 0.05)

    PMID 28236285 · one of two readings recorded this

  • diastolic blood pressure pre-post

    increases, p = 0.01

    a small but statistically significant increase in DBP associated with ADHD medication (SMD 0.18, 95% CI 0.09–0.26, p < 0.01; 17 studies)

    PMID 28236285 · one of two readings recorded this

  • diastolic blood pressure pre-post

    increases, p = 0.02

    AMP (SMD 0.16, 95% confidence interval [CI] 0.03–0.29, p = 0.02; four studies)

    PMID 28236285 · one of two readings recorded this

  • diastolic blood pressure pre-post

    increases, p = 0.01

    ATX (SMD 0.22, 95% CI 0.10–0.34, p < 0.01; seven studies)

    PMID 28236285 · one of two readings recorded this

  • diastolic blood pressure pre-post

    no effect, p = 0.11

    The effect for MPH was not significant (SMD 0.16, 95% CI −0.04 to 0.36, p = 0.11; ten studies)

    PMID 28236285 · one of two readings recorded this

  • heart rate change at 12 months

    increases

    and at 12 months (DBP +1.6 mmHg; SBP +1.6 mmHg; HR +5.6 bpm) compared with baseline

    PMID 28236285 · one of two readings recorded this

  • heart rate change at 24 months

    no effect

    There were no statistically significant effects at 24 months in comparison with the baseline (DBP +1.11 mmHg; SBP +2.13 mmHg; HR +0.21 bpm)

    PMID 28236285 · one of two readings recorded this

  • heart rate change at 6 months

    increases

    Fuentes et al. observed small changes at 6 months for all cardiovascular parameters (DBP +1.3 mmHg; SBP +0.8 mmHg; HR +7.9 bpm)

    PMID 28236285 · one of two readings recorded this

  • heart rate change at first measurement

    increases

    (average 6 weeks; mean changes: DBP +1 mmHg; SBP +0.75 mmHg; HR +3.35 bpm)

    PMID 28236285 · one of two readings recorded this

  • heart rate change at first measurement

    increases

    A peak in DBP (mean +1.7 mmHg) and HR (mean +3.7 bpm) was reported at the first measurement (average 3.2 months after baseline)

    PMID 28236285 · one of two readings recorded this

  • heart rate pre-post

    increases, p = 0.01

    Pooled pre–post effects across all three medications were small but statistically significant (SMD 0.32, 95% CI 0.20–0.43, p < 0.01; 17 studies)

    PMID 28236285 · one of two readings recorded this

  • heart rate pre-post

    increases, p = 0.01

    AMP (SMD 0.37, 95% CI 0.13–0.60, p < 0.01; five studies)

    PMID 28236285 · one of two readings recorded this

  • heart rate pre-post

    increases, p = 0.01

    ATX (SMD 0.43, 95% CI 0.26–0.60, p < 0.01; seven studies)

    PMID 28236285 · one of two readings recorded this

  • heart rate pre-post

    no effect, p = 0.07

    the effects for MPH were not statistically significant (SMD 0.20, 95% CI −0.02 to 0.41, p = 0.07; 10 studies)

    PMID 28236285 · one of two readings recorded this

  • other cardiovascular effects, difference between medications

    no effect, p = 0.007

    There were no significant differences between the medication treatments, (F(2) = 3.006, p = 0.007)

    PMID 28236285 · one of two readings recorded this

  • pre-post change in systolic and diastolic blood pressure and heart rate on methylphenidate, amphetamines and atomoxetine in children with ADHD (medication arms only, pre-post SMD)

    increases, MPH SBP pre-post SMD 0.25, 95% CI 0.08-0.42

    Not recorded as a finding: the result compares a group with itself, not with a control

    MPH (SMD 0.25, 95% CI 0.08–0.42, p < 0.01; ten trials), AMP (SMD 0.09, 95% CI 0.03–0.15, p < 0.01; four studies) and ATX (SMD 0.16, 95% CI 0.04–0.27, p = 0.01; seven studies) each had small but statistically significant pre–post effects on SBP.

    PMID 28236285 · one of two readings recorded this

  • pre-post change in systolic blood pressure, diastolic blood pressure and heart rate on methylphenidate, standardised mean difference of within-group change; setting not stated

    increases, SBP pre-post SMD 0.25, 95% CI 0.08-0.42 for MPH

    Not recorded as a finding: the result compares a group with itself, not with a control

    MPH (SMD 0.25, 95% CI 0.08–0.42, p < 0.01; ten trials), AMP (SMD 0.09, 95% CI 0.03–0.15, p < 0.01; four studies) and ATX (SMD 0.16, 95% CI 0.04–0.27, p = 0.01; seven studies) each had small but statistically significant pre–post effects on SBP.

    PMID 28236285 · one of two readings recorded this

  • systolic blood pressure change at 12 months

    no effect

    Arcieri et al. reported no statistically significant effects on DBP (+0.13 mmHg) and SBP (+0.36 mmHg) at 12 months in comparison with baseline

    PMID 28236285 · one of two readings recorded this

  • systolic blood pressure change at 12 months

    increases

    and at 12 months (DBP +1.6 mmHg; SBP +1.6 mmHg; HR +5.6 bpm) compared with baseline

    PMID 28236285 · one of two readings recorded this

  • systolic blood pressure change at 24 months

    no effect

    There were no statistically significant effects at 24 months in comparison with the baseline (DBP +1.11 mmHg; SBP +2.13 mmHg; HR +0.21 bpm)

    PMID 28236285 · one of two readings recorded this

  • systolic blood pressure change at 6 months

    increases

    Fuentes et al. observed small changes at 6 months for all cardiovascular parameters (DBP +1.3 mmHg; SBP +0.8 mmHg; HR +7.9 bpm)

    PMID 28236285 · one of two readings recorded this

  • systolic blood pressure change at first measurement

    increases

    (average 6 weeks; mean changes: DBP +1 mmHg; SBP +0.75 mmHg; HR +3.35 bpm)

    PMID 28236285 · one of two readings recorded this

  • systolic blood pressure change at first measurement

    increases

    Similar results were reported on SBP (mean +1.6 mmHg)

    PMID 28236285 · one of two readings recorded this

  • systolic blood pressure pre-post, effect of publication year

    no effect

    Studies published before 2007 reported higher ESs (SMD 0.37) than studies after 2007 (SMD −0.02)

    PMID 28236285 · one of two readings recorded this

  • systolic blood pressure pre-post, effect of publication year

    increases

    Studies published before 2007 reported higher ESs (SMD 0.37) than studies after 2007 (SMD −0.02)

    PMID 28236285 · one of two readings recorded this

  • systolic blood pressure pre-post, moderator test of publication year

    modulates, p = 0.05

    There was a significant effect of publication year on SBP for MPH treatment (F(1) = 5.346, p = 0.05)

    PMID 28236285 · one of two readings recorded this

  • systolic blood pressure pre-post

    increases, p = 0.01

    Across all medications together there was a small and significant pre–post effect (SMD 0.18, 95% CI 0.10–0.27, p < 0.01; 17 studies)

    PMID 28236285 · one of two readings recorded this

  • systolic blood pressure pre-post

    increases, p = 0.01

    AMP (SMD 0.09, 95% CI 0.03–0.15, p < 0.01; four studies)

    PMID 28236285 · one of two readings recorded this

  • systolic blood pressure pre-post

    increases, p = 0.01

    ATX (SMD 0.16, 95% CI 0.04–0.27, p = 0.01; seven studies)

    PMID 28236285 · one of two readings recorded this

  • systolic blood pressure pre-post

    increases, p = 0.01

    MPH (SMD 0.25, 95% CI 0.08–0.42, p < 0.01; ten trials)

    PMID 28236285 · one of two readings recorded this

  • abdominal pain, parallel group vs cross-over trials

    no effect, p = 0.23

    we found no difference in the risk of abdominal pain between parallel group and cross-over trials (P=0.23; Fig 5)

    PMID 28617801 · one of two readings recorded this

  • abdominal pain, subgroup difference by dose

    no effect, p = 0.95

    abdominal pain (P=0.95)

    PMID 28617801 · one of two readings recorded this

  • abdominal pain, subgroup difference by type

    no effect, p = 0.72

    abdominal pain (P=0.72)

    PMID 28617801 · one of two readings recorded this

  • abdominal pain, subgroup difference short-term vs long-term

    no effect, p = 0.18

    abdominal pain (P=0.18)

    PMID 28617801 · one of two readings recorded this

  • abdominal pain

    increases, n = 1837

    increased abdominal pain (RR 1.61; 95% CI 1.27 to 2.04; 1,837 participants; 33 trials, Fig 5)

    PMID 28617801 · one of two readings recorded this

  • abdominal pain

    no effect

    abdominal pain (RR 1.30; 95% CI 1.00 to 1.69; 13 trials)

    PMID 28617801 · one of two readings recorded this

  • decreased appetite, low dose

    no effect

    low dose (RR 2.87; 95% CI 0.87 to 9.45)

    PMID 28617801 · one of two readings recorded this

  • decreased appetite, moderate/high dose

    increases, p = 0.86

    moderate/high dose (RR 2.57; 95% CI 1.96 to 3.35), (test for subgroup differences: P=0.86)

    PMID 28617801 · one of two readings recorded this

  • decreased appetite, parallel-group vs cross-over trials

    no effect, p = 0.41

    We found no significant difference in the risk of the main outcome decreased appetite between parallel-group and cross-over trials (P = 0.41; I2 = 0%; Fig 2)

    PMID 28617801 · one of two readings recorded this

  • decreased appetite, subgroup difference by type

    no effect, p = 0.11

    decreased appetite (P=0.11)

    PMID 28617801 · one of two readings recorded this

  • decreased appetite, subgroup difference short-term vs long-term

    no effect, p = 0.53

    decreased appetite (P=0.53)

    PMID 28617801 · one of two readings recorded this

  • decreased appetite

    increases, n = 1901

    We found that methylphenidate decreased appetite (RR 3.04; 95% CI 2.35 to 3.94; 1,901 participants; 36 trials, Fig 2)

    PMID 28617801 · one of two readings recorded this

  • decreased appetite

    increases, n = 2962

    In parallel group trials methylphenidate was associated with decreased appetite (RR 3.66; 95% CI 2.56 to 5.23; 2,962 participants; 16 trials, Fig 2)

    PMID 28617801 · one of two readings recorded this

  • decreased weight, subgroup difference by dose

    no effect, p = 0.72

    decreased weight (P=0.72)

    PMID 28617801 · one of two readings recorded this

  • decreased weight, subgroup difference by type

    no effect, p = 0.28

    decreased weight (P=0.28)

    PMID 28617801 · one of two readings recorded this

  • decreased weight

    increases, n = 859

    decreased weight (RR 3.89; 95% CI 1.43 to 10.59; 859 participants; 7 trials, Fig 3)

    PMID 28617801 · one of two readings recorded this

  • diarrhea, subgroup difference by dose

    no effect, p = 0.94

    diarrhea (P=0.94)

    PMID 28617801 · one of two readings recorded this

  • diarrhoea

    no effect

    diarrhoea (RR 1.07; 95% CI 0.41 to 2.77; 5 trials)

    PMID 28617801 · one of two readings recorded this

  • dyspepsia, subgroup difference by type

    no effect, p = 0.98

    dyspepsia (P=0.98)

    PMID 28617801 · one of two readings recorded this

  • dyspepsia, subgroup difference short-term vs long-term

    no effect, p = 0.98

    dyspepsia (P=0.98)

    PMID 28617801 · one of two readings recorded this

  • dyspepsia

    no effect

    dyspepsia (RR 1.80; 95% CI 0.71 to 4.54; 2 trials)

    PMID 28617801 · one of two readings recorded this

  • Egger test publication bias, abdominal pain

    no effect, p = 0.136

    Egger’s regression intercept (bias) was 1.11 (two-tailed P = 0.136)

    PMID 28617801 · one of two readings recorded this

  • Egger test publication bias, decreased appetite

    unclear, p = 0.02

    Eggers’ regression intercept (bias) was 8.717 (two-tailed P = 0.020)

    PMID 28617801 · one of two readings recorded this

  • Egger test publication bias, nausea

    no effect, p = 0.215

    Egger’s regression intercept (bias) was 2.16 (two-tailed P = 0.215)

    PMID 28617801 · one of two readings recorded this

  • Egger test publication bias, vomiting

    no effect, p = 0.271

    Egger’s regression intercept (bias) was 1.438 (two-tailed P = 0.271)

    PMID 28617801 · one of two readings recorded this

  • increased appetite

    increases, n = 68

    One trial observed that methylphenidate increased appetite (RR 0.20; 95% CI 0.08 to 0.50; 68 participants; 1 trial)

    PMID 28617801 · one of two readings recorded this

  • increased appetite

    no effect

    increased appetite (RR 0.07; 95% CI 0.00 to 1.43; 1 trial)

    PMID 28617801 · one of two readings recorded this

  • nausea, subgroup difference by dose

    no effect, p = 0.63

    nausea (P=0.63)

    PMID 28617801 · one of two readings recorded this

  • nausea, subgroup difference by type

    no effect, p = 0.2

    nausea (P=0.20)

    PMID 28617801 · one of two readings recorded this

  • nausea, subgroup difference short-term vs long-term

    no effect, p = 0.38

    nausea (P=0.38)

    PMID 28617801 · one of two readings recorded this

  • nausea

    no effect

    nausea (RR 1.30; 95% CI 0.85 to 1.99; 11 trials)

    PMID 28617801 · one of two readings recorded this

  • risk of decreased appetite, decreased weight, abdominal pain and other gastrointestinal adverse events, pooled risk ratio versus placebo or no intervention

    increases, decreased appetite RR 3.66; 95% CI 2.56 to 5.23 in parallel group trials

    Not recorded as a finding: this platform holds no node for the endpoint

    In parallel group trials methylphenidate was associated with decreased appetite (RR 3.66; 95% CI 2.56 to 5.23; 2,962 participants; 16 trials, Fig 2) and decreased weight (RR 3.89; 95% CI 1.43 to 10.59; 859 participants; 7 trials, Fig 3).

    PMID 28617801 · one of two readings recorded this

  • risk of individual gastrointestinal adverse events (decreased appetite, decreased weight, abdominal pain, nausea, vomiting, diarrhoea, dyspepsia) vs placebo or no intervention, pooled risk ratios

    increases, decreased appetite RR 3.66, 95% CI 2.56 to 5.23

    Not recorded as a finding: this platform holds no node for the endpoint

    In parallel group trials methylphenidate was associated with decreased appetite (RR 3.66; 95% CI 2.56 to 5.23; 2,962 participants; 16 trials, Fig 2) and decreased weight (RR 3.89; 95% CI 1.43 to 10.59; 859 participants; 7 trials, Fig 3).

    PMID 28617801 · one of two readings recorded this

  • Trial Sequential Analysis required information size, abdominal pain

    For abdominal pain the required information size was 4,830 participants

    PMID 28617801 · one of two readings recorded this

  • Trial Sequential Analysis required information size, decreased appetite

    For the outcome decreased appetite the required information size was 14,286 participants

    PMID 28617801 · one of two readings recorded this

  • vomiting, subgroup difference by dose

    no effect, p = 0.68

    vomiting (P=0.68)

    PMID 28617801 · one of two readings recorded this

  • vomiting, subgroup difference by type

    no effect, p = 0.85

    vomiting (P=0.85)

    PMID 28617801 · one of two readings recorded this

  • vomiting, subgroup difference short-term vs long-term

    no effect, p = 0.95

    vomiting (P=0.95)

    PMID 28617801 · one of two readings recorded this

  • vomiting

    no effect

    vomiting (RR 1.17; 95% CI 0.76 to 1.79; 11 trials)

    PMID 28617801 · one of two readings recorded this

  • hyperactivity, parent-rated

    decreases, p = 0.02, n = 71

    and parents (mean difference (MD) -6.61 points, 95% CI -12.19 to -1.03, rated on the hyperactivity subscale of the Aberrant Behviour Checklist, range 0 to 48; 2 studies, 71 participants; P = 0.02; low-quality evidence)

    PMID 29159857 · one of two readings recorded this

  • hyperactivity, teacher-rated

    decreases, p = 0.001, n = 73

    hyperactivity, as rated by teachers (SMD -0.78, 95% confidence interval (CI) -1.13 to -0.43; 4 studies, 73 participants; P < 0.001; low-quality evidence)

    PMID 29159857 · one of two readings recorded this

  • inattention, teacher-rated

    decreases, p = 0.04, n = 51

    teacher-rated inattention (MD -2.72 points, 95% CI -5.37 to -0.06, rated on the inattention subscale of the Swanson, Nolan and Pelham, Fourth Version questionnaire, range 0 to 27; 2 studies, 51 participants; P = 0.04; low-quality evidence)

    PMID 29159857 · one of two readings recorded this

  • overall ASD, teacher-rated

    no effect, p = 0.15, n = 36

    or overall ASD (SMD -0.53, 95% CI -1.26 to 0.19; 2 studies, 36 participants; P = 0.15; low-quality evidence)

    PMID 29159857 · one of two readings recorded this

  • reduced appetite, parent-rated

    increases, p = 0.001, n = 74

    reduced appetite as rated by parents (risk ratio 8.28, 95% CI 2.57 to 26.73; 2 studies, 74 participants; P < 0.001; very low-quality evidence)

    PMID 29159857 · one of two readings recorded this

  • social interaction, teacher-rated

    no effect, p = 0.07, n = 63

    or benefits social interaction (SMD -0.51, 95% CI -1.07 to 0.05; 3 studies, 63 participants; P = 0.07; very low-quality evidence)

    PMID 29159857 · one of two readings recorded this

  • stereotypical behaviours, teacher-rated

    no effect, p = 0.19, n = 69

    stereotypical behaviours (SMD -0.34, 95% CI -0.84 to 0.17; 3 studies, 69 participants; P = 0.19; low-quality evidence)

    PMID 29159857 · one of two readings recorded this

  • teacher- and parent-rated hyperactivity (SMD; Aberrant Behavior Checklist hyperactivity subscale), teacher-rated inattention (SNAP-IV inattention subscale), ASD core symptoms, parent-rated reduced appetite

    increases, reduced appetite RR 8.28, 95% CI 2.57 to 26.73

    Not recorded as a finding: this platform holds no node for the endpoint

    The only adverse effect that was significantly more likely with treatment was reduced appetite as rated by parents (risk ratio 8.28, 95% CI 2.57 to 26.73; 2 studies, 74 participants; P < 0.001; very low-quality evidence).

    PMID 29159857 · one of two readings recorded this

  • Egger regression publication bias, rs6551665 (LPHN3) and SLC6A3 10-repeat VNTR

    unclear, p = 0.01

    Egger’s regression tests detected significant publication bias (asymmetry) for both DNA variants (P = 0.01)

    PMID 29230023 · one of two readings recorded this

  • Heterogeneity I2, 10-repeat VNTR (SLC6A3)

    p = 0.0001

    10-repeat VNTR (SLC6A3) (χ2 = 47.37, P < 0.0001; I2 = 68%)

    PMID 29230023 · one of two readings recorded this

  • Heterogeneity I2, 4-repeat VNTR (DRD4)

    p = 0.14

    4-repeat VNTR (DRD4) (χ2 = 8.23, P = 0.14; I2 = 39%)

    PMID 29230023 · one of two readings recorded this

  • Heterogeneity I2, 7-repeat VNTR (DRD4)

    p = 0.02

    7-repeat VNTR (DRD4) (χ2 = 11.36, P = 0.02; I2 = 65%)

    PMID 29230023 · one of two readings recorded this

  • Heterogeneity I2, rs1800544 (ADRA2A)

    p = 0.002

    rs1800544 (ADRA2A) (χ2 = 14.73, P = 0.002; I2 = 80%)

    PMID 29230023 · one of two readings recorded this

  • Heterogeneity I2, rs1947274 (LPHN3)

    p = 0.005

    rs1947274 (LPHN3) (χ2= 10.44, P = 0.005; I2 = 81%)

    PMID 29230023 · one of two readings recorded this

  • Heterogeneity I2, rs28386840 (SLC6A2)

    p = 0.34

    rs28386840 (SLC6A2) (χ2 = 2.18, P = 0.34; I2 = 8%)

    PMID 29230023 · one of two readings recorded this

  • Heterogeneity I2, rs4680 (COMT)

    p = 0.003

    rs4680 (COMT) (χ2 = 19.96, P = 0.003; I2 = 70%)

    PMID 29230023 · one of two readings recorded this

  • Heterogeneity I2, rs5569 (SLC6A2)

    p = 0.43

    rs5569 (SLC6A2) (χ2 = 5.92, P = 0.43; I2 = 0%)

    PMID 29230023 · one of two readings recorded this

  • Heterogeneity I2, rs5661665 (LPHN3)

    p = 0.005

    rs5661665 (LPHN3) (χ2 = 12.96, P = 0.005; I2 = 77%)

    PMID 29230023 · one of two readings recorded this

  • Meta-regression of effect size on study quality, all significant variants without publication bias

    no effect, p = 0.4885

    This analysis found no significant effect size associations with MPH response (k = 55, b = 0.0626, P = 0.4885)

    PMID 29230023 · one of two readings recorded this

  • MPH response by DRD4 48bp VNTR 4-repeat homozygous vs other genotypes

    increases, p = 0.005

    The homozygous 4-repeat genotype demonstrated an association with improved MPH response when compared to other genotypes (OR: 1.66, CI: 1.16–2.37, P = 0.005)

    PMID 29230023 · one of two readings recorded this

  • MPH response by DRD4 VNTR 7-repeat allele vs others

    no effect, p = 0.05

    meta-analysis of the 7-repeat allele versus others did not reach statistical significance (OR: 0.68, CI: 0.47–1.00, P = 0.05)

    PMID 29230023 · one of two readings recorded this

  • MPH response by rs1800544 (ADRA2A) G allele vs C allele carriers

    increases, p = 0.01

    Furthermore, the G allele of rs1800544 (ADRA2A) was associated with improved MPH response compared to C allele carriers (OR: 1.69, CI: 1.12–2.55, P = 0.01)

    PMID 29230023 · one of two readings recorded this

  • MPH response by rs1947274 (LPHN3)

    no effect, p = 0.7

    Two variants within the LPHN3 gene were not significantly associated with MPH response: rs5661665 (OR: 1.07, CI: 0.84–1.37, P = 0.59) and rs1947274 (OR: 0.95, CI: 0.71–1.26, P = 0.70)

    PMID 29230023 · one of two readings recorded this

  • MPH response by rs2284411 (GRIN2B) C/C genotype

    increases, p = 0.05

    The C/C genotype of rs2284411 (GRIN2B) was associated with improved MPH treatment response (OR: 9.03, CI: 1.02–79.99, P = 0.05)

    PMID 29230023 · one of two readings recorded this

  • MPH response by rs28386840 (SLC6A2) T allele vs A/A genotype

    increases, p = 0.0001

    For rs28386840 (SLC6A2), the T allele was associated with an improved response to MPH treatment when compared to the A/A genotype (OR: 2.93, CI: 1.76–4.90, P < 0.0001)

    PMID 29230023 · one of two readings recorded this

  • MPH response by rs3746544 (SNAP25) T/T genotype, first study

    no effect, p = 0.86

    the T/T genotype of rs3746544 (SNAP25) was not significantly associated with treatment response in two studies (OR:1.12, CI: 0.55–2.25, P = 0.86;OR: 1.66, CI: 0.51–5.39, P = 0.41)

    PMID 29230023 · one of two readings recorded this

  • MPH response by rs3746544 (SNAP25) T/T genotype, second study

    no effect, p = 0.41

    the T/T genotype of rs3746544 (SNAP25) was not significantly associated with treatment response in two studies (OR:1.12, CI: 0.55–2.25, P = 0.86;OR: 1.66, CI: 0.51–5.39, P = 0.41)

    PMID 29230023 · one of two readings recorded this

  • MPH response by rs4680 (COMT) Val/Val genotype vs Met allele carriers

    increases, p = 0.02

    Meta-analysis of the rs4680 variant in COMT revealed that the Val/Val genotype was associated with improved treatment response compared with Met allele carriers (OR: 1.40, CI: 1.04–1.87, P = 0.02)

    PMID 29230023 · one of two readings recorded this

  • MPH response by rs5569 (SLC6A2) G/G genotype vs A allele carriers

    increases, p = 0.0007

    The G/G genotype of rs5569 (SLC6A2) was associated with an improved MPH response compared to A allele carriers (OR: 1.73, CI: 1.26–2.37, P = 0.0007)

    PMID 29230023 · one of two readings recorded this

  • MPH response by rs5661665 (LPHN3)

    no effect, p = 0.59

    Two variants within the LPHN3 gene were not significantly associated with MPH response: rs5661665 (OR: 1.07, CI: 0.84–1.37, P = 0.59) and rs1947274 (OR: 0.95, CI: 0.71–1.26, P = 0.70)

    PMID 29230023 · one of two readings recorded this

  • MPH response by rs6265 (BDNF) Val/Val genotype

    no effect, p = 0.07

    The Val/Val genotype of rs6265 (BDNF) was not significantly associated with MPH response, despite having a substantial effect size (OR: 6.67, CI: 0.84–52.89, P = 0.07)

    PMID 29230023 · one of two readings recorded this

The whole record — 626 rows